What to Know When Your Child Has Narcolepsy
Narcolepsy is a disorder that affects the brain’s ability to control sleep and alertness. Without proper treatment, it can hinder your child’s school, social, and personal life. Learn more about how to support your child though their condition. (Source: WebMD Health)
Source: WebMD Health - July 26, 2021 Category: Consumer Health News Source Type: news

Complementary and Alternative Treatments for Narcolepsy
If you have narcolepsy, certain complementary or alternative medicines like yoga or herbal teas may help ease or manage some of the symptoms. (Source: WebMD Health)
Source: WebMD Health - July 23, 2021 Category: Consumer Health News Source Type: news

Tips and Tricks to Manage Narcolepsy Day-to-Day
Narcolepsy can make life complicated, but with the help of a sleep doctor and some tips and tricks to get you through the day, you can manage your days better. (Source: WebMD Health)
Source: WebMD Health - July 20, 2021 Category: Consumer Health News Source Type: news

Is Narcolepsy an Autoimmune Disorder?
We look at evidence that points to narcolepsy as an autoimmune disorder and what that could mean for diagnosis and treatment. (Source: WebMD Health)
Source: WebMD Health - July 19, 2021 Category: Consumer Health News Source Type: news

What Things Can Make Narcolepsy Worse?
Narcolepsy attacks can come and go. How well you sleep at night might affect how often you have bouts of extreme sleepiness during the day. (Source: WebMD Health)
Source: WebMD Health - July 16, 2021 Category: Consumer Health News Source Type: news

How to Navigate Relationships With Narcolepsy
Narcolepsy can affect many different parts of your life, including the relationships you build. Learn about the challenges of maintaining relationships when you have narcolepsy and ways to navigate those relationships. (Source: WebMD Health)
Source: WebMD Health - July 12, 2021 Category: Consumer Health News Source Type: news

Narcolepsy and Your Diet
Learn about the link between narcolepsy and obesity, best foods for narcolepsy, how and when to eat, and if a low-carb or keto diet helps with symptoms. (Source: WebMD Health)
Source: WebMD Health - July 9, 2021 Category: Consumer Health News Source Type: news

Levels of GHB in hair after regular application - Nebel A, Mayer G, Hess C, Heidbreder A, Martz W, Veit F.
Gamma hydroxybutyrate (GHB) is a central nervous system depressant that is an approved drug for the treatment of narcolepsy with cataplexy and other syndromes. Due to its dose dependent stimulating, relaxing or sedative effects, illicit abuses include recr... (Source: SafetyLit)
Source: SafetyLit - July 5, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

European guideline and expert statements on the management of narcolepsy in adults and children - Bassetti CLA, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, Dolenc-Groselj L, Jennum P, Khatami R, Manconi M, Mayer G, Partinen M, Pollm ├Ącher T, Reading P, Santamaria J, Sonka K, Dauvilliers Y, Lammers GJ.
BACKGROUND AND AIM: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and children. ... (Source: SafetyLit)
Source: SafetyLit - July 2, 2021 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

European guideline and expert statements on the management of narcolepsy in adults and children - Bassetti CLA, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, Dolenc-Groselj L, Jennum P, Khatami R, Manconi M, Mayer G, Partinen M, Pollm ├Ącher T, Reading P, Santamaria J, Sonka K, Dauvilliers Y, Lammers GJ.
BACKGROUND AND PURPOSE: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and childre... (Source: SafetyLit)
Source: SafetyLit - June 28, 2021 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
U.S. Food and Drug Administration published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy by means of greater safety compared to Xy... Biopharmaceuticals, FDA Jazz Pharmaceuticals, Xywav, Cataplexy, Narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2021 Category: Pharmaceuticals Source Type: news

Once-Nightly Sodium Oxybate Agent Effective in Narcolepsy Once-Nightly Sodium Oxybate Agent Effective in Narcolepsy
An investigational, once-nightly formulation of sodium oxybate is safe and effective for treating both subjective and objective symptoms of narcolepsy, results from the phase 3 REST-ON trial show.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 30, 2021 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news

NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
STANS, Switzerland, April 5, 2021 -- (Healthcare Sales & Marketing Network) -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and developmen... Biopharmaceuticals, Neurology, Personnel NLS Pharmaceutics, Quilience, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2021 Category: Pharmaceuticals Source Type: news

Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
DUBLIN, Ireland, March 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

On-the-road driving performance of patients with central disorders of hypersomnolence - van der Sluiszen NNJJM, Urbanus B, Lammers GJ, Overeem S, Ramaekers JG, Vermeeren A.
INTRODUCTION: Excessive Daytime Sleepiness is a core symptom of narcolepsy and idiopathic hypersomnia, which impairs driving performance. Adequate treatment improves daytime alertness, but it is unclear whether driving performance completely normalizes. Th... (Source: SafetyLit)
Source: SafetyLit - February 8, 2021 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

How the brain paralyzes you while you sleep
(University of Tsukuba) Researchers from the University of Tsukuba have discovered a group of neurons in the mouse brainstem that control muscle tone. Inhibiting these neuronal cells caused mice to move during REM sleep, reminiscent of REM sleep behavior disorders. These neurons were also responsible for episodes of cataplexy in a mouse model of narcolepsy; inhibiting them reduced the number of cataplexic bouts. These circuits could thus be a new target for treating these sleep disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 14, 2021 Category: International Medicine & Public Health Source Type: news

Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix(R) (pitolisant)
Citrine was founded by Eight Roads, F-Prime Capital, and Vivo Capital; and closed an $80 Million Series A financing earlier this year Company is focused on bringing important rare disease therapies to China while accelerating the rare disease drug devel... Biopharmaceuticals, Licensing Citrine Medicine, Bioprojet, Wakix, pitolisant, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 28, 2020 Category: Pharmaceuticals Source Type: news

Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX(R) (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy
WAKIX is the first and only non-scheduled treatment approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 -- (Healthcare Sales & Marketing Network) -- Harmony Bioscienc... Biopharmaceuticals, FDA Harmony Biosciences, WAKIX, pitolisant, cataplexy, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 14, 2020 Category: Pharmaceuticals Source Type: news

Harmony Biosciences Receives FDA Approval for Expanded Use of Wakix (pitolisant) for the Treatment Of Cataplexy in Adult Patients with Narcolepsy
PLYMOUTH MEETING, PA and CHICAGO, IL, October 13, 2020— Harmony Biosciences Holdings, Inc. ( " Harmony " ) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 13, 2020 Category: Drugs & Pharmacology Source Type: news

Depression and suicidal thoughts in untreated and treated narcolepsy: systematic analysis - Barateau L, Lopez R, Chenini S, Pesenti C, Rassu AL, Jaussent I, Dauvilliers Y.
OBJECTIVES: To assess the frequency and determinants of depressive symptoms and suicidal thoughts in adults with narcolepsy type 1 (NT1) and controls, as well as the changes after NT1 management, and the risk factors of major depressive episode (MDE) and s... (Source: SafetyLit)
Source: SafetyLit - September 25, 2020 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

Narcolepsy Drug Doesn't Raise Odds for Birth Defects: Study
This study is based on twice as many pregnancies as earlier studies, and we... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 4, 2020 Category: General Medicine Source Type: news

Narcolepsy drug did not increase risk of fetal malformation
(Karolinska Institutet) Modafinil is used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant. Now, a large registry study involving over two million pregnant women in Sweden and Norway shows that there is no such association. The study, which is published in JAMA, was conducted by researchers at Sweden's Karolinska Institutet and the Norwegian Institute of Public Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2020 Category: International Medicine & Public Health Source Type: news

'Pay-for-delay' plan blocked cheap generic challengers to Peninsula company's narcolepsy drug for years, lawsuits claim
Legal maneuvering by the company effectively blocked a generic drug for narcolepsy from entering the market since 2011. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 12, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

'Pay-for-delay' plan blocked cheap generic challengers to Peninsula company's narcolepsy drug for years, lawsuits claim
Legal maneuvering by the company effectively blocked a generic drug for narcolepsy from entering the market since 2011. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 12, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Can a peer support the process of self-management in narcolepsy? A qualitative narrative analysis of a narcoleptic patient - Franceschini C, Fante C, Filardi M, Folli MC, Brazzi F, Pizza F, D'Anselmo A, Ingravallo F, Antelmi E, Plazzi G.
INTRODUCTION: Narcolepsy type 1 (NT1) is a chronic and rare sleep disorder typically arising during adolescence and young adulthood. The main symptoms are excessive daytime sleepiness and cataplexy, a prototypical fall down elicited by huge emotions. Socia... (Source: SafetyLit)
Source: SafetyLit - August 3, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

FDA Okays Low-Sodium Treatment Option for Narcolepsy FDA Okays Low-Sodium Treatment Option for Narcolepsy
The novel drug Xywav is an oxybate product with a unique composition that results in 92% less sodium than sodium oxybate (Zyrem).FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 22, 2020 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years Xywav contains 92 percent less sodium per nightly dose than sodium oxybate, a curre... Biopharmaceuticals, Neurology, FDA Jazz Pharmaceuticals, Xywav, Cataplexy, Narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2020 Category: Pharmaceuticals Source Type: news

Jazz Pharmaceuticals expands sleep disorder drug portfolio with FDA approval of Xywav
The Food and Drug Administration has approved Jazz Pharmaceuticals' new drug application for Xywav, a new sleep disorder drug. Xywav was approved by the FDA, Tuesday night, to treat cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy. Jazz stock was up nearly 4.6% to $110.34 per share in early morning trading. Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. People with narcolepsy often… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 22, 2020 Category: Biotechnology Authors: John George Source Type: news

FDA Approves Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
DUBLIN, July 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 22, 2020 Category: Drugs & Pharmacology Source Type: news

Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management - Marinelli E, Beck R, Malvasi A, Faro AFL, Zaami S.
Gamma-hydroxybutyrate (GHB) is a central nervous system depressant primarily used as a recreational drug of abuse, but also for the treatment of narcolepsy with cataplexy in adult patients and as an adjuvant for control of alcohol withdrawal syndrome. The ... (Source: SafetyLit)
Source: SafetyLit - July 4, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

What Are the Signs of Narcolepsy
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 19, 2020 Category: General Medicine Source Type: news

A cautionary tale about narcolepsy and deferrals to the civilian network - Kinkennon S.
The transformation of Army medicine has been a topic of great concern for all military physicians, regardless of specialty. It has been proposed that 18,000 uniformed military medical personnel be cut (approximately 22% of 2019 uniformed personnel). Pe... (Source: SafetyLit)
Source: SafetyLit - March 11, 2020 Category: International Medicine & Public Health Tags: Commentary Source Type: news

Narcoleptic 15-year-old suffers sudden muscle paralysis if she giggles
Jordan Coomer, from Indiana, suffers from cataplexy, which causes sudden muscle paralysis if she giggles or feels strong emotion. It's a complication of narcolepsy, which can be caused by an infection. (Source: the Mail online | Health)
Source: the Mail online | Health - January 27, 2020 Category: Consumer Health News Source Type: news

Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
DUBLIN, Jan. 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 22, 2020 Category: Drugs & Pharmacology Source Type: news

Jazz Pharmaceuticals sleep disorder drug approved by European Commission
The European Commission has approved Sunosi, a Jazz Pharmaceuticals sleep disorder treatment. Sunosi was approved, in 75- and 150-milligram doses, to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea who did not respond to primary sleep apnea therapies such as continuous positive airway pressure. Jazz Pharmaceuticals, which is based in Dublin, Ireland, has major operations in Philadelphia where the company has nearly 200 employees.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 21, 2020 Category: Biotechnology Authors: John George Source Type: news

Risk of burn injury in patients with narcolepsy: a nationwide population-based cohort study - Chang ET, Lin CL, Chen SF, Shen YC.
Narcolepsy is a rare brain disorder characterized by excessive daytime sleepiness (EDS), cataplexy, hypnagogic hallucinations, and sleep paralysis. Stimulants have been used to relieve the symptoms of EDS. Narcolepsy symptoms may pose a risk to burn injury... (Source: SafetyLit)
Source: SafetyLit - January 16, 2020 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

EMA Panel Backs Solriamfetol (Sunosi) for Narcolepsy, OSA EMA Panel Backs Solriamfetol (Sunosi) for Narcolepsy, OSA
The dual-acting dopamine and norepinephrine reuptake inhibitor showed durable effects in reducing excessive sleepiness in patients with narcolepsy or obstructive sleep apnea (OSA).International Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 15, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Solriamfetol is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea If approved by the European Commission for... Biopharmaceuticals, Regulatory Jazz Pharmaceuticals, solriamfetol, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2019 Category: Pharmaceuticals Source Type: news

Novel, Low-Sodium Drug Promising for Narcolepsy Novel, Low-Sodium Drug Promising for Narcolepsy
A novel drug with a low-sodium formulation is both safe and effective for treating symptoms of narcolepsy in adult patients, results from a phase 3 trial suggest.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 3, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

A case of a sleepy taxi driver presenting with narcolepsy - Miskoff JA, Chaudhri M.
Narcolepsy is a sleep disorder, which can manifest in childhood, or adolescence by causing excessive daytime sleepiness, hallucinations, sleep attacks or cataplexy. Although presentation can vary, nearly all patients present with excessive daytime sleepine... (Source: SafetyLit)
Source: SafetyLit - August 21, 2019 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

FDA Approves Wakix (pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy
PLYMOUTH MEETING, PA, August 15, 2019— Harmony Biosciences, LLC (Harmony) announced today that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness (EDS) in adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 15, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Okays Pitolisant (Wakix) for Narcolepsy FDA Okays Pitolisant (Wakix) for Narcolepsy
The FDA has approved pitolisant, a first-in-class, nonscheduled treatment option with a novel mechanism of action for adults with narcolepsy.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 15, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Harmony Biosciences Announces FDA Approval Of WAKIX(R) (Pitolisant), A First-In-Class Medication For The Treatment Of Excessive Daytime Sleepiness In Adult Patients With Narcolepsy
WAKIX represents the first and only non-scheduled treatment approved for patients with narcolepsy in the U.S. PLYMOUTH MEETING, Pa., Aug. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Harmony Biosciences, LLC (Harmony) announced today that the ... Biopharmaceuticals, FDA Harmony Biosciences, WAKIX, pitolisant, excessive daytime sleepiness, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 15, 2019 Category: Pharmaceuticals Source Type: news

Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients - Antelmi E, Pizza F, Donadio V, Filardi M, Sosero YL, Incensi A, Vandi S, Moresco M, Ferri R, Marelli S, Ferini-Strambi L, Liguori R, Plazzi G.
To search for discriminating biomarkers, 30 patients with idiopathic rapid-eye-movements sleep behavior disorder (iRBD) were compared with 17 patients with RBD within narcolepsy type 1. Both groups underwent extensive examinations, including skin biopsy se... (Source: SafetyLit)
Source: SafetyLit - August 8, 2019 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

Medical News Today: Everything you need to know about methylphenidate
Methylphenidate is a stimulant drug that doctors prescribe to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. Learn about how it works, its side effects, and typical dosages here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Medical News Today: Everything you need to know about Adderall
In this article, learn all about Adderall, a type of stimulant medication that doctors sometimes prescribe to treat ADHD or narcolepsy. We cover the uses, side effects, dosage, and more. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Medical News Today: Is hair loss a side effect of Adderall?
Adderall is a combination drug for the short-term treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Although it is generally a safe and effective drug, it can cause a range of side effects. Alopecia, or hair loss, is a potential but uncommon side effect of taking Adderall. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 5, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

The risk of hospitalization for motor vehicle accident injury in narcolepsy and the benefits of stimulant use: a nationwide cohort study in Taiwan - Tzeng NS, Hsing SC, Chung CH, Chang HA, Kao YC, Mao WC, Yang CCH, Kuo TBJ, Chen TY, Chien WC.
STUDY OBJECTIVES: To examine the risk of hospitalization for motor vehicle accident injury (MVAI) in patients with narcolepsy and the effects of stimulant use on MVAI occurrence in patients with narcolepsy. METHODS: This is a population-based, retr... (Source: SafetyLit)
Source: SafetyLit - June 4, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Medical News Today: What are the side effects and risks of Ritalin?
Ritalin (methylphenidate) is a stimulant medication for the treatment of ADHD and narcolepsy. Ritalin can cause side effects and has the potential for misuse and addiction. Researchers are investigating the long-term safety and effectiveness of this drug in children and adolescents. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 31, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Personal trainer, 24, falls asleep up to 16 TIMES a day because of her narcolepsy
Belle Hutt, from Oxford, was terrified of her sudden sleep attacks because her condition also caused sleep paralysis and hallucinations. She now controls her sleeping with an exercise routine. (Source: the Mail online | Health)
Source: the Mail online | Health - May 29, 2019 Category: Consumer Health News Source Type: news